Cargando…

In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma

BACKGROUND: Bone marrow aspirate concentrate (BMAC) including high densities of stem cells and progenitor cells may possess a stronger bone regenerative capability compared with Platelet-rich plasma (PRP), which contains enriched growth factors. The objective of this study was to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Weijian, Sumita, Yoshinori, Ohba, Seigo, Kawasaki, Takako, Nagai, Kazuhiro, Ma, Guowu, Asahina, Izumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395629/
https://www.ncbi.nlm.nih.gov/pubmed/22808272
http://dx.doi.org/10.1371/journal.pone.0040833
_version_ 1782238005144059904
author Zhong, Weijian
Sumita, Yoshinori
Ohba, Seigo
Kawasaki, Takako
Nagai, Kazuhiro
Ma, Guowu
Asahina, Izumi
author_facet Zhong, Weijian
Sumita, Yoshinori
Ohba, Seigo
Kawasaki, Takako
Nagai, Kazuhiro
Ma, Guowu
Asahina, Izumi
author_sort Zhong, Weijian
collection PubMed
description BACKGROUND: Bone marrow aspirate concentrate (BMAC) including high densities of stem cells and progenitor cells may possess a stronger bone regenerative capability compared with Platelet-rich plasma (PRP), which contains enriched growth factors. The objective of this study was to evaluate the effects of human BMAC and PRP in combination with β-tricalcium phosphate (β-TCP) on promoting initial bone augmentation in an immunodeficient mouse model. METHODOLOGY/PRINCIPAL FINDINGS: BMAC and PRP were concentrated with an automated blood separator from the bone marrow and peripheral blood aspirates. β-TCP particles were employed as a scaffold to carry cells. After cell counting and FACS characterization, three groups of nude mice (BMAC+TCP, PRP+TCP, and a TCP control) were implanted with graft materials for onlay placement on the cranium. Samples were harvested after 4 weeks, and serial sections were prepared. We observed the new bone on light microscopy and performed histomorphometric analysis. After centrifugation, the concentrations of nucleated cells and platelets in BMAC were increased by factors of 2.8±0.8 and 5.3±2.4, respectively, whereas leucocytes and platelets in PRP were increased by factors of 4.1±1.8 and 4.4±1.9, respectively. The concentrations of CD34-, CD271-, CD90-, CD105-, and CD146-positive cells were markedly increased in both BMAC and PRP. The percentage of new bone in the BMAC group (7.6±3.9%) and the PRP group (7.2±3.8%) were significantly higher than that of TCP group (2.7±1.4%). Significantly more bone cells in the new bone occurred in sites transplanted with BMAC (552±257) and PRP (491±211) compared to TCP alone (187±94). But the difference between the treatment groups was not significant. CONCLUSIONS/SIGNIFICANCE: Both human BMACs and PRP may provide therapeutic benefits in bone tissue engineering applications. These fractions possess a similar ability to enhance early-phase bone regeneration.
format Online
Article
Text
id pubmed-3395629
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33956292012-07-17 In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma Zhong, Weijian Sumita, Yoshinori Ohba, Seigo Kawasaki, Takako Nagai, Kazuhiro Ma, Guowu Asahina, Izumi PLoS One Research Article BACKGROUND: Bone marrow aspirate concentrate (BMAC) including high densities of stem cells and progenitor cells may possess a stronger bone regenerative capability compared with Platelet-rich plasma (PRP), which contains enriched growth factors. The objective of this study was to evaluate the effects of human BMAC and PRP in combination with β-tricalcium phosphate (β-TCP) on promoting initial bone augmentation in an immunodeficient mouse model. METHODOLOGY/PRINCIPAL FINDINGS: BMAC and PRP were concentrated with an automated blood separator from the bone marrow and peripheral blood aspirates. β-TCP particles were employed as a scaffold to carry cells. After cell counting and FACS characterization, three groups of nude mice (BMAC+TCP, PRP+TCP, and a TCP control) were implanted with graft materials for onlay placement on the cranium. Samples were harvested after 4 weeks, and serial sections were prepared. We observed the new bone on light microscopy and performed histomorphometric analysis. After centrifugation, the concentrations of nucleated cells and platelets in BMAC were increased by factors of 2.8±0.8 and 5.3±2.4, respectively, whereas leucocytes and platelets in PRP were increased by factors of 4.1±1.8 and 4.4±1.9, respectively. The concentrations of CD34-, CD271-, CD90-, CD105-, and CD146-positive cells were markedly increased in both BMAC and PRP. The percentage of new bone in the BMAC group (7.6±3.9%) and the PRP group (7.2±3.8%) were significantly higher than that of TCP group (2.7±1.4%). Significantly more bone cells in the new bone occurred in sites transplanted with BMAC (552±257) and PRP (491±211) compared to TCP alone (187±94). But the difference between the treatment groups was not significant. CONCLUSIONS/SIGNIFICANCE: Both human BMACs and PRP may provide therapeutic benefits in bone tissue engineering applications. These fractions possess a similar ability to enhance early-phase bone regeneration. Public Library of Science 2012-07-12 /pmc/articles/PMC3395629/ /pubmed/22808272 http://dx.doi.org/10.1371/journal.pone.0040833 Text en Zhong et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Zhong, Weijian
Sumita, Yoshinori
Ohba, Seigo
Kawasaki, Takako
Nagai, Kazuhiro
Ma, Guowu
Asahina, Izumi
In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title_full In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title_fullStr In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title_full_unstemmed In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title_short In Vivo Comparison of the Bone Regeneration Capability of Human Bone Marrow Concentrates vs. Platelet-Rich Plasma
title_sort in vivo comparison of the bone regeneration capability of human bone marrow concentrates vs. platelet-rich plasma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395629/
https://www.ncbi.nlm.nih.gov/pubmed/22808272
http://dx.doi.org/10.1371/journal.pone.0040833
work_keys_str_mv AT zhongweijian invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT sumitayoshinori invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT ohbaseigo invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT kawasakitakako invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT nagaikazuhiro invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT maguowu invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma
AT asahinaizumi invivocomparisonoftheboneregenerationcapabilityofhumanbonemarrowconcentratesvsplateletrichplasma